NCT06242392View on ClinicalTrials.gov

The Correlation Between HRD Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer

Not yet recruitingOBSERVATIONAL

Enrollment

250

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

May 1, 2026

Study Completion Date

July 1, 2026

Conditions

Ovarian Neoplasms

Interventions

GENETIC

homologous recombination deficiency

Homologous Recombination Deficiency (HRD) refers to a disruption or deficiency in the homologous recombination repair (HRR) pathway, which is a crucial mechanism in cells for repairing DNA double-strand breaks (DSBs). This pathway is particularly important for maintaining genomic stability.

All Listed Sponsors

collaborator

Fujian Provincial Hospital

OTHER

lead

Fujian Cancer Hospital

OTHER_GOV

NCT06242392 - The Correlation Between HRD Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer | Biotech Hunter | Biotech Hunter